Blood substitutes: Why haven't we been more successful?

Trends in Biotechnology

Volumn 32, Issue 4, 2014, Pages 177-185

  Alayash, Abdu I ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Blood substitutes; Heme; Hemoglobin; Oxidative toxicity

Indexed keywords

ANIMALS; BLOOD SUBSTITUTES; HEMOGLOBIN; NITRIC OXIDE; OXYGEN; TOXICITY;

ALTERNATIVE PATH; BLOOD VESSEL WALLS; HEME; LONG-TERM STORAGE; OXIDATIVE TOXICITY; OXYGEN CARRIER; PATHOPHYSIOLOGICAL CHANGES; SAFETY CONCERNS;

PORPHYRINS;

BLOOD SUBSTITUTE; DIASPIRIN CROSSLINKED HEMOGLOBIN; GLOBIN; HEME; HEMOGLOBIN GLUTAMER 256; HEMOGLOBIN RAFFIMER; HEMOSPAN; NITRIC OXIDE; POLYMERIZED HEMOGLOBIN; PYRIDOXYLHEMOGLOBIN; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AUTOREGULATION; BINDING AFFINITY; BLOOD VESSEL WALL; DRUG INTOXICATION; EXTRAVASATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; OXYGEN TENSION; PH; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALIA;

BLOOD SUBSTITUTES; HEME; HEMOGLOBIN; OXIDATIVE TOXICITY;

ANIMALS; BIOTECHNOLOGY; BLOOD SUBSTITUTES; HEME; HEMOGLOBINS; HUMANS; MODELS, MOLECULAR; OXIDATIVE STRESS;

EID: 84896546440     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2014.02.006     Document Type: Review

References (52)

1. Kim H-W., Greenburg A.G. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Artif. Organs 2004, 28:813-827.
2. Alayash A.I. Setbacks in blood substitutes research and development: a biochemical perspective. Clin. Lab. Med. 2010, 106:76-85.
3. Adamson J.G., Moore C. Hemolink, an O-Raffinose crosslinked hemoglobin-based oxygen carrier. Blood Substitutes, Principles, Methods, Products and Clinical Trials 1998, 62-79. Karger Landes Systems, Basel, Switzerland. T.M.S. Chang (Ed.).
4. Varnado C.L., et al. Development of recombinant hemoglobin-based oxygen carriers. Antioxid. Redox Signal. 2013, 18:2314-2328.
5. Buehler P.W., Alayash A.I. Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems. Transfusion 2004, 44:1516-1530.
6. Manalo D.J., et al. Acellular haemoglobin attenuates hypoxia-inducible factor-1alpha (HIF-1alpha) and its target genes in haemodiluted rats. Biochem. J. 2008, 414:461-469.
7. Chen J-Y., et al. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics 2009, 64:803-813.
8. Silverman T.A., Weiskopf R.B. Hemoglobin-based oxygen carriers: current status and future directions. Anesthesiology 2009, 111:946-963.
9. Creteure J., Vincent J-L. Potential uses of hemoglobin-based oxygen carriers in critical care medicine. Crit. Care Clin. 2009, 25:311-324.
10. Buehler P.W., et al. Hemoglobin-based oxygen carriers: from mechanisms of toxicity and clearance to rational drug design. Trends Mol. Med. 2010, 16:447-457.
11. Marret E., et al. The effects of a polymerized bovine-derived hemoglobin solution in a rabbit model of arterial thrombosis and bleeding. Anesth. Analg. 2004, 98:604-610.
12. Burhop K., et al. Review of hemoglobin-induced myocardial lesions. Artif. Cells Blood Substit. Immobil. Biotechnol. 2004, 32:353-374.
13. Regan R.F., et al. Hemoglobin potentiates excitotoxic injury in cortical cell culture. J. Neurotrauma 1996, 13. 223-231.
14. Turner C.P., et al. Heme-oxygenase-1 is induced in glia throughout brain by subarachnoid hemoglobin. J. Cereb. Blood Flow Metab. 1998, 18:257-273.
15. Butt O., et al. Blood-brain barrier disruption and oxidative stress in guinea pig after systemic exposure to modified cell-free hemoglobin. Am. J. Pathol. 2011, 178:1316-1328.
16. Eich R.F., et al. Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry 1996, 35:6976-6983.
17. Alayash A.I., et al. Nitric oxide binding to human ferrihemoglobins cross-linked between either alpha or beta subunits. Arch. Biochem. Biophys. 1993, 303:332-338.
18. Alayash A.I. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants?. Nat. Biotechnol. 1999, 17:545-549.
19. Gould S.A., Moss G.S. Clinical development of human polymerized hemoglobin as a blood substitute. World J. Surg. 1996, 20:1200-1207.
20. Buehler P.W., et al. Chemical characterization of diaspirin cross-linked hemoglobin polymerized with poly(ethylene glycol). Anal. Chem. 2006, 78:4634-4641.
21. Abassi Z., et al. Effects of polymerization on the hypertensive action of diaspirin crosslinked hemoglobin in rats. J. Lab. Clin. Med. 1997, 29:603-610.
22. Liu X. Nitric oxide uptake by erythrocytes is primarily limited by extracellular diffusion not membrane resistance. J. Biol. Chem. 2002, 277:26194-26199.
23. Alayash A.I. oxygen therapeutics: can we tame haemoglobin?. Nat. Rev. Drug Discov. 2004, 3:152-159.
24. Robinson J.M., Lancaster J.R. Hemoglobin-mediated hypoxia-induced vasodilation via nitric oxide. Am. J. Respir. Cell Mol. Biol. 2005, 32:257-261.
25. Roche C.J., et al. Generating s-nitrosothiols from hemoglobin: mechanisms, conformational dependence, and physiological relevance. J. Biol. Chem. 2013, 288:22408-22425.
26. Moon-Massat P., et al. The effect of HBOC-201 and sodium nitrite resuscitation after uncontrolled haemorrhagic shock in swine. Injury 2012, 43:638-647.
27. Winslow R.M. Cell-free oxygen carriers: scientific foundations, clinical development, and new directions. Biochim. Biophys. Acta 2008, 1784:1382-1386.
28. Winslow R.M. Oxygen: the poison is in the dose. Transfusion 2013, 53:424-437.
29. Conover C.D., et al. The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models. Artif. Cells Blood Substit. Immobil. Biotechnol. 1999, 27:93-107.
30. Manjula B.N., et al. Conjugation of multiple copies of polyethylene glycol to hemoglobin facilitated through thiolation: influence on hemoglobin structure and function. Protein J. 2005, 3:133-146.
31. Harrington J.P., et al. Structural and redox behavior of OxyVita, a zero-linked polymeric hemoglobin: comparison with natural acellular polymeric hemoglobins. Artif. Cells Blood Substit. Immobil. Biotechnol. 2010, 38:64-68.
32. Wettstein R., et al. Resuscitation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Crit. Care Med. 2003, 31:1824-1830.
33. Winslow R.M., et al. Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. J. Appl. Physiol. 1998, 85:993-1003.
34. Elmer J., et al. hemoglobin-based oxygen carrier for hemorrhagic shock. Resuscitation 2012, 83:1824-1830.
35. Reeder B.J. The redox activity of hemoglobins: from physiologic functions to pathologic mechanisms. Antioxid. Redox Signal. 2010, 13:1087-1123.
36. Jia Y., et al. Structural basis of peroxide-mediated changes in human hemoglobin: a novel oxidative pathway. J. Biol. Chem. 2007, 282:4894-4907.
37. Buehler P.W., et al. Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig. J. Pharmacol. Exp. Ther. 2007, 323:49-60.
38. Dunne J., et al. Ascorbate removes key precursors to oxidative damage by cell-free haemoglobin in vitro and in vivo. Biochem. J. 2006, 399:513-524.
39. Buehler P.W., Alayash A.I. Oxidation of hemoglobin: mechanism of control in vitro and in vivo. Transfus. Alt. Transfus. Med. 2007, 9:204-212.
40. Reeder B.J. Toxicity of myoglobin and haemoglobin: oxidative stress in patients with rhabdomyolysis and subarachnoid haemorrhage. Biochem. Soc. Trans. 2002, 30:745-7481.
41. Buehler P.W., et al. Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood 2009, 113:2578-2586.
42. Fitzgerald M.C., et al. A synthetic haemoglobin-based oxygen carrier and the reversal of cardiac hypoxia secondary to severe anemia following trauma. Med. J. Aust. 2011, 194:471-473.
43. Figueiredo R.T. Characterization of heme as activator of Toll-like receptor 4. J. Biol. Chem. 2007, 282:20221-20229.
44. Belcher J., et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2013, 126:377-390.
45. Buehler P.W., et al. Blood aging, safety, and transfusion: capturing the "radical" menace. Antioxid. Redox Signal. 2011, 14:1713-1728.
46. Feng L., et al. Structure of oxidized alpha-haemoglobin bound to AHSP reveals a protective mechanism for haem. Nature 2005, 435:697-701.
47. Schaer D., et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013, 121:1276-1284.
48. Mauk M.R., et al. An alternative view of the proposed alternative activities of hemopexin. Protein Sci. 2011, 20:791-805.
49. Boretti F.S., et al. Intravascular sequestration within the haptoglobin complex is effective in treating hypertensive and oxidative effects of plasma free hemoglobin. J. Clin. Invest. 2009, 119:2271-2280.
50. Hemoglobin: Structure, Function, Evolution, and Pathophysiology 1983, Benjamin/Cummings. R.E. Dickerson, I. Geis (Eds.).
51. Mollan T.L., et al. Alpha-hemoglobin stabilizing protein (AHSP) markedly decreases the redox potential and reactivity of α subunits of human HbA with peroxide. J. Biol. Chem. 2013, 288:4288-4898.
52. Olsson M.G., et al. Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α(1)-microglobulin. Antioxid. Redox Signal. 2012, 17:813-846.